AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
Europe's STOXX 600 eked out minor gains on Tuesday led by gains in industrials as investors assessed a slew of downbeat ...
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a ...
Analyst Sachin Jain from Bank of America Securities maintained a Buy rating on AstraZeneca (AZN – Research Report) and keeping the price ...
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...
China's investigation of AstraZeneca's top executive in the country is raising questions about the company's tactics there.
Bullish option flow detected in AstraZeneca (AZN) with 5,692 calls trading, 5x expected, and implied vol increasing almost 3 points to 33.14%.
Britain's benchmark FTSE 100 edged lower on Tuesday, hurt by AstraZeneca's fall on a potential China probe, while investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback